Spyre Therapeutics, Inc. — Director's Dealing 2016

Apr 7, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2016-04-06

Reporting Person: Mahatme Sandesh (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Director Stock Option (right to buy)	$12.81	2025-06-14	Common Stock (23809)		Direct

Footnotes

F1: The stock option vested and became exercisable as to 1/36th of the shares subject to the option on July 15, 2015, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.